HOB Biotech Group Corp Ltd (688656) - Total Liabilities
Based on the latest financial reports, HOB Biotech Group Corp Ltd (688656) has total liabilities worth CN¥85.18 Million CNY (≈ $12.46 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are HOB Biotech Group Corp Ltd's assets to evaluate the company's liquid asset resilience ratio.
HOB Biotech Group Corp Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how HOB Biotech Group Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of HOB Biotech Group Corp Ltd.
HOB Biotech Group Corp Ltd Competitors by Total Liabilities
The table below lists competitors of HOB Biotech Group Corp Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Plejd AB (publ)
F:3CA
|
Germany | €346.32 Million |
|
SINOPEC Engineering (Group) Co. Ltd
F:1NS
|
Germany | €59.40 Billion |
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
USA | $942.23 Million |
|
Sichuan Zigong Conveying Machine Group Co Ltd
SHE:001288
|
China | CN¥3.28 Billion |
|
British American Tobacco PLC
LSE:BATS
|
UK | GBX59.79 Billion |
|
Frey SA
PA:FREY
|
France | €2.07 Billion |
|
Upwork Inc
NASDAQ:UPWK
|
USA | $669.26 Million |
|
CHINA FOODS UNSP.ADR/20
F:CFH0
|
Germany | €7.82 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down HOB Biotech Group Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See HOB Biotech Group Corp Ltd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HOB Biotech Group Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HOB Biotech Group Corp Ltd (2016–2025)
The table below shows the annual total liabilities of HOB Biotech Group Corp Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥111.30 Million ≈ $16.29 Million |
-49.56% |
| 2024-12-31 | CN¥220.67 Million ≈ $32.29 Million |
+59.30% |
| 2023-12-31 | CN¥138.52 Million ≈ $20.27 Million |
-16.04% |
| 2022-12-31 | CN¥164.99 Million ≈ $24.14 Million |
+75.67% |
| 2021-12-31 | CN¥93.92 Million ≈ $13.74 Million |
+4.33% |
| 2020-12-31 | CN¥90.02 Million ≈ $13.17 Million |
-32.59% |
| 2019-12-31 | CN¥133.54 Million ≈ $19.54 Million |
+44.99% |
| 2018-12-31 | CN¥92.10 Million ≈ $13.48 Million |
+41.27% |
| 2017-12-31 | CN¥65.20 Million ≈ $9.54 Million |
-4.04% |
| 2016-12-31 | CN¥67.94 Million ≈ $9.94 Million |
-- |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as an in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immune assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB Biotech Group Corp.,Ltd was founded in 2009 and is ba… Read more